AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampli

AIM ImmunoTech Inc. (NYSE American: AIM) has commenced its Phase 2 study to evaluate the potential therapeutic effects of Ampligen® on individuals with post-COVID conditions. The enrollment and dosing of the first subject have already taken place, with encouraging preliminary data on Ampligen. The study is projected to be fully enrolled by Q4 2023. In order to facilitate this study, AIM has esta..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 11.
  • textsms

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen

AIM ImmunoTech Inc. has received authorizations from the Competent Authority and Ethics Board in the Netherlands to begin a Phase 1b/2 study evaluating Ampligen, its TLR-3 agonist, in combination with durvalumab, a checkpoint inhibitor. The study aims to explore the safety and clinical benefit of this combination therapy in patients with metastatic pancreatic ductal adenocarcinoma. Patient enrol..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms